“After six months of treatment with Ozempic, I hardly drink anymore”: will anti-obesity drugs precipitate the decline in wine consumption?

Jean-Louis* did not go there with joy of heart. Diabetic, he accepted treatment with semaglutide, the molecule sold under the names Ozempic and Wegovy, “with reluctance,” he says, “because I had a lot of preconceptions about the product and the conditions of use, which are very restrictive.” What he didn't expect was the effect on his drinking. “The first two months, I didn’t drink it at all, I just didn’t want to,” he admits. Then he took another drink: “It had the same effect on me as usual, but I noticed that I was saturated more quickly.” Six months and ten kilos less later, the results are clear: “I hardly drink anymore. I have a desire that is more psychological than physical.” His testimony is not isolated. For two years, stories of patients who, on Ozempic, Wegovy or Mounjaro, discover themselves indifferent to the aperitif have multiplied, first on forums, then in medical journals.

In the United States…